Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) - Total debt
Total debt on the balance sheet as of December 2023 : $25.23 M
According to Adaptimmune Therapeutics's latest financial reports the company's total debt is $25.23 M. A company’s total debt is the sum of all current and non-current debts.
Adaptimmune Therapeutics - Total debt on balance sheet (from 2018 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $25.23 M | 9.35% |
| 2022-12-31 | $23.07 M | -9.39% |
| 2021-12-31 | $25.46 M | 7.41% |
| 2020-12-31 | $23.71 M | -6.87% |
| 2019-12-31 | $25.45 M | |
| 2018-12-31 | $N/A | |
| 2013-06-30 | $1.53 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $0.13 B | 448.48% | 🇳🇱 Netherlands |
 Novavax NVAX | $0.22 B | 807.79% | 🇺🇸 USA |
 Exelixis EXEL | $0.18 B | 652.70% | 🇺🇸 USA |
 Enzo Biochem ENZ | $7.18 M | -71.54% | 🇺🇸 USA |